SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination

Blood

Volumn 118, Issue 22, 2011, Pages 5803-5812

  Klatt, Nichole R ^a   Vinton, Carol L ^a   Lynch, Rebecca M ^a   Canary, Lauren A ^a   Ho, Jason ^a   Darrah, Patricia A ^a   Estes, Jacob D ^b   Seder, Robert A ^a   Moir, Susan L ^a   Brenchley, Jason M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; IMMUNOGLOBULIN A; LEISHMANIA MAJOR POLYPROTEIN VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD34 SELECTION; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL SPECIFICITY; CONTROLLED STUDY; HELPER CELL; IMMUNE RESPONSE; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION;

EID: 82155178683     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365874     Document Type: Article

References (56)

1. Brenchley JM, Ruff LE, Casazza JP, Koup RA, Price DA, Douek DC. Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol. 2006; 80(14):6801-6809. (Pubitemid 44025180)
2. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749-759. (Pubitemid 39299461)
3. Centlivre M, Sala M, Wain-Hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS. 2007;21(1):1-11. (Pubitemid 44912531)
4. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417(6884):95-98. (Pubitemid 34498823)
5. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 Infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77(21):11708-11717. (Pubitemid 37271669)
6. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol. 2005; 5(10):783-792. (Pubitemid 41400852)
7. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol. 2003;21: 265-304. (Pubitemid 37174533)
8. Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med. 2010;207(13):2869-2881.
9. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis. 2010;10(7):499-503.
10. Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology. 2011;411(2):206-215.
11. Helmreich E, Kern M, Eisen HN. The secretion of antibody by isolated lymph node cells. J Biol Chem. 1961;236:464-473.
12. Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, Sallusto F. Dissecting the human immunologic memory for pathogens. Immunol Rev. 2011; 240(1):40-51.
13. Yoshida T, Mei H, Dorner T, et al. Memory B and memory plasma cells. Immunol Rev. 2010;237(1): 117-139.
14. Rosenberg YJ. Isotype-specific T cell regulation of immunoglobulin expression. Immunol Rev. 1982;67:33-58. (Pubitemid 13232933)
15. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7(3):235-239.
16. Mestecky J, Jackson S, Moldoveanu Z, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses. 2004; 20(9):972-988. (Pubitemid 39369704)
17. Scamurra RW, Nelson DB, Lin XM, et al. Mucosal plasma cell repertoire during HIV-1 infection. J Immunol. 2002;169(7):4008-4016.
18. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005; 191(9):1442-1450. (Pubitemid 40563355)
19. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205(8): 1797-1805.
20. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309(8):453-458. (Pubitemid 13041485)
21. Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A. 2001;98(18):10362-10367. (Pubitemid 32803025)
22. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest. 1992;89(2):561-566.
23. Martínez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol. 1987;138(11):3720-3724. (Pubitemid 17078240)
24. Martínez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol. 2002;14(5):528-532.
25. Ng VL. B-lymphocytes and autoantibody profiles in HIV disease. Clin Rev Allergy Immunol. 1996; 14(4):367-384. (Pubitemid 126441541)
26. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9(4):235-245.
27. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev. 2010;237(1):72-89.
28. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621-663.
29. Betts MR, Price DA, Brenchley JM, et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol. 2004; 172(10):6407-6417. (Pubitemid 38621250)
30. Klatt NR, Chahroudi A, Silvestri G. Human immunodeficiency viruses (Retroviridae): Pathogenesis. In: Mahy BWJ, Van Regenmortel MHV, eds. Encyclopedia of Virology. Vol. 5. Oxford: Elsevier; 2008;345- 353.
31. Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol. 2004;78(3):1160-1168. (Pubitemid 38095826)
32. De Boer RJ, Mohri H, Ho DD, Perelson AS. Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol. 2003; 170(5):2479-2487. (Pubitemid 36245637)
33. Paiardini M, Cervasi B, Dunham R, Sumpter B, Radziewicz H, Silvestri G. Cell-cycle dysregulation in the immunopathogenesis of AIDS. Immunol Res. 2004;29(1-3):253-268.
34. Mascart-Lemone F, Gerard M, Libin M, et al. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J Infect Dis. 1995; 172(5):1253-1260.
35. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol. 1991; 84(2):185-189.
36. Dieye TN, Sow PS, Simonart T, et al. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. Vaccine. 2001;20(5-6):905-913. (Pubitemid 34015832)
37. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen.ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000;14(1):11-21. (Pubitemid 30072073)
38. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med. 2008;9(1):57-61.
39. Rigaud M, Borkowsky W, Muresan P, et al. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis. 2008;198(8):1123-1130.
40. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol. 2005; 21(5):244-249. (Pubitemid 40544642)
41. Freidag BL, Mendez S, Cheever AW, et al. Immunological and pathological evaluation of rhesus macaques infected with Leishmania major. Exp Parasitol. 2003;103(3-4):160-168. (Pubitemid 36918191)
42. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007;13(7):843-850. (Pubitemid 47038186)
43. Rhee EG, Mendez S, Shah JA, et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med. 2002;195(12):1565- 1573. (Pubitemid 34666070)
44. Gramiccia M, Gradoni L, Troiani M. HIV-Leishmania co-infections in Italy. Isoenzyme characterization of Leishmania causing visceral leishmaniasis in HIV patients. Trans R Soc Trop Med Hyg. 1992; 86(2):161-163.
45. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334-359. (Pubitemid 351555511)
46. Schraner C, Hasse B, Hasse U, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis. 2005;40(12):e120-e124.
47. Klatt NR, Harris LD, Vinton CL, et al. Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol. 2010;3(4):387-398.
48. Roederer M, Nozzi JL, Nason MX. SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011; 79(2): 167-174.
49. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434(7037): 1093-1097. (Pubitemid 40663481)
50. Betts MR, Nason MC, West SM, et al. HIV non-progressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107(12):4781-4789. (Pubitemid 43882629)
51. Kannanganat S, Kapogiannis BG, Ibegbu C, et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol. 2007;81(21): 12071-12076. (Pubitemid 47623838)
52. Garber DA, Silvestri G, Barry AP, et al. Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. J Clin Invest. 2004;113(6):836-845. (Pubitemid 38544142)
53. Heath SL, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature. 1995;377(6551):740-744.
54. Dullaers M, Li D, Xue Y, et al. A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity. 2009;30(1):120-129.
55. Chevalier MF, Julg B, Pyo A, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011;85(2):733-741.
56. Pallikkuth S, Pilakka Kanthikeel S, Silva SY, Fischl M, Pahwa R, Pahwa S. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol. 2011;186(11):6173-6181.